^
    Back
    Association details:
    Biomarker:EGFR S768I
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lung Cancer
    Title:

    EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer

    Published date:
    05/16/2021
    Excerpt:
    Nine patients with S786I mutations received TKIs, resulting in an ORR of 50%, mPFS of 18.2 months (2.79-not reached), and mOS of 33.4 months (95% CI, 16.14-not reached).
    DOI:
    10.1016/j.cllc.2021.04.009